echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > BeiGene tislelizumab's new indications for marketing applications are accepted in China

    BeiGene tislelizumab's new indications for marketing applications are accepted in China

    • Last Update: 2021-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, BeiGene announced that the Center for Drug Evaluation (CDE) of the National Food and Drug Administration (NMPA) of China has accepted its anti-PD-1 antibody drug Bezean (tislelizumab injection) for the treatment of the past New indication marketing application (sBLA) for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed or become intolerable after receiving first-line standard chemotherapy


    The marketing application for this new indication is based on the results of a randomized, open, multi-center global phase 3 clinical trial RATIONALE 302


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.